Response to dasatinib in a patient with concomitant chronic myeloid leukemia and chronic lymphocytic leukemia

Acta Haematologica

Volumn 124, Issue 2, 2010, Pages 105-109

  Serpa, Mariana ^a,b   Bendit, Israel ^b   Seguro, Fernanda ^a,b   Xavier, Flavia ^a   Cavalcante, Marcela ^a   Steinbaum, Daniel ^a   Nardinelli, Luciana ^b   Aldred, Vera Lucia ^b   De Paula, Henrique Moura ^b   Dorlhiac Llacer, Pedro Enrique ^b  

^a Instituto do Cancer do Estado de Sao Paulo   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bowen's disease; Chronic lymphocytic leukemia; Chronic myeloid leukemia; Dasatinib

Indexed keywords

DASATINIB; IMATINIB; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

AGED; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; GENE DELETION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LABORATORY TEST; LUNG TOXICITY; LYMPHOCYTE COUNT; MALE; NEUTROPENIA; PRIORITY JOURNAL; BIOPSY; COMPLICATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PATHOLOGY; TREATMENT OUTCOME;

AGED; BIOPSY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES; TREATMENT OUTCOME;

EID: 77955632932     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000318009     Document Type: Article

References (17)

1. Gribben JG: How I treat CLL up front. Blood 2010;115: 186-197.
2. Song Z, Lu P, Furman RR, Leonard JP, Martin P, Tyrell L, Lee FY, Knowles DM, Coleman M, Wang YL: Activities of SYK and PLC72 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasa-tinib. Clin Cancer Res 2010; 16: 587-599.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer statistics. CA Cancer J Clin 2006; 56: 106-130.
4. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM: The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164-172.
5. Cortes J: Natural history and staging of chronic myelogenous leukemia. Hematol Oncol Clin N Am 2004; 18:569-584.
6. Amrein L, Panasci L, Gibson SB, Johnston JB, Soulières D, Aloyz R: Primary del 17 chronic lymphocytic leukaemia lymphocytes are hypersensitive to dasatinib in vitro. Br J H aem atol 2009;147:396-398 .
7. Veldurthy A, Patz M, Hagist S, Pallasch CP, Wendtner C, Hallek M, Krause G: The ki-nase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood 2008; 112:1443-1452.
8. Hallaert DYH, Jaspers A, Van Noesel CJ, Van Oers MJH, Kater AP, Eldering E: c-Abl ki-nase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood 2008; 1 12:5141-5149.
9. Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L, Pinna LA, Zambello R, Semenzato G, Donella-Deana A: Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 2005; 115:369-378.
10. Kim DH, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ, Lee JJ, Lipton JH: Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haemato-logica 2009; 94: 135-139.
11. Mustjoki S, Ekblom M, Arsitila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M, Kovanen P, lauinolli T, Liesveld J, Paquet te R, Pinilla-Ibarz J, Rau-hala A, Shah N, Simonsson B, Sinisalo M, StegmannJL, Stenke L, Porkka K: Clonal expansion of T/NK-cells during tyrosine ki-nase inhibitor dasatinib therapy. Leukemia 2009; 23: 1398-1405.
12. Amrein PC, Attar E, Takvorian T, Hochberg E, Ballen KK, Leahy KM, Neuberg D, Brown JR: Dasatinib has activity in relapsed/refractory chronic lymphocytic leukemia (CLL/ SLL), a phase II tria l. Blood 2008; 112 : 1084a.
13. Ga rg RJ, Wierda W, Fayad L , Estrov Z , Bickel S, O'Brien S: Phase II study of dasatinib in patients with relapsed CLL. Blood 2008; 112: 4197a.
14. Pitini V, Arrigo C, Altavilla G: Dasatinib induces a response in chronic lymphocytic leukemia. Blood 2009; 113:498.
15. Bhagavathi S, Borromeo V, Desai H, Crisan D: Case report and literature review: a rare patient with chronic myeloid leukemia and chronic lymphocytic leukemia. Ann Clin Lab Sci 2008; 38:405-409.
16. Tecchio C, Nichele I, Todeschini G, Pizzolo G, Ambrosetti A: Dasatinib-induced response in a rare case of chronic lymphocytic leukaemia associated with chronic myeloid leukaemia. Br J Haematol 2009; 146:222-223.
17. Amrein L, Hernandez TA, Ferrario C, Johnston J, Gibson SB, Panascy L, Aloyz R: Dasa-tinib sensitizes primary chronic lymphocyt-ic leukaemia lymphocytes to chlorambucil and f ludarabine in vitro. Br J Haematol 2008; 143:698-706.